Search

Your search keyword '"Gebbia, N"' showing total 552 results
Start Over Author "Gebbia, N"
552 results on '"Gebbia, N"'

1. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer

Author

Floriani, I., Rulli, E., Cropalato Di Tullio, M., Poli, D., Galli, F., Biagioli, E., De Simone, I., Mangano, S., Tonato, M., Zucca, E., Valsecchi, M.G., Bajetta, E., Di Bartolomeo, M., Labianca, R., Amadori, D., Falcone, A., Di Costanzo, F., Daniele, B., Pinto, C., Comella, G., Nitti, D., Mini, E., De Placido, S., Marchet, A., Catena, L., Schiavo, M., Pinotti, G., Proserpio, I., Rosati, G., Bordonaro, R., Cordio, S., Burrafato, G., Bochicchio, A.M., Aieta, M., Fazio, N., Spada, F., Amoroso, V., Marini, G., Soto Parra, H., Novello, G., Massidda, B., Ionta, M.T., Comandè, M., Venezia, R., Bertolini, A., Menatti, E., Zanlorenzi, L., Colombo, A., Iop, A., Bonura, S., Mazza, E., Viganò, M., Ardizzoia, A., Dell'Oro, S., Lo Re, G., Santeufemia, D., Buonadonna, A., Luisi, D., Ucci, G., Di Lucca, G., Bonetti, A., Bergamo, F., Alù, M., Vastola, F., Marchetti, P., Corsi, D.C., Massa, E., Di Pinto, G., Duro, M., Oliani, C., Franchini, M., Inzoli, A., Gebbia, N., Repetto, L., Rota, S., Frontini, L., Mosconi, S., Quadri, A., De Grossi, S., Bidoli, P., Cazzaniga, M.E., Villa, F., Foa, P., Ferrari, D., Aitini, E., Rabbi, C., Barni, S., Petrelli, F., Giordano, M., Luchena, G., Pirovano, M., Nasisi, A., Catalano, V., Giordani, P., Zaniboni, A., Leone, F., Ferrario, S., Beretta, G.D., Menichetti, E.T., Conte, D., Mari, D., Giannicola, R., Pierantoni, C., Luporini, A.G., Ravaioli, A., Tassinari, D., Nicolini, M., Frassineti, G.L., Turci, D., Zumaglini, F., Tamberi, S., Piancastelli, A., Cruciani, G., Landi, L., Minuti, G., Cantore, M., Orlandi, M., Mambrini, A., Ciarlo, A., Cavaciocchi, D., Del Monte, F., Ricci, S., Brunetti, M.I., Lencioni, M., Sisani, M., Sozzi, P., Granetto, C., Chiara, S., Galetto, A.S., Ribecco, A.S., DeCensi, A., Ciuffreda, L., Baldini, E.E., Camisa, R., Todeschini, R., Santoro, A., Rimassa, L., Carnaghi, C., Pressiani, T., Boni, C., Rondini, E., Gnoni, R., Gasperoni, S., Cavanna, L., Palladino, M.A., Mattioli, R., Laici, G., Pucci, F., Alessio, M.D., Bernardini, I., Tomasello, G., Baldino, G., Rossetti, R., Giaquinta, S., Di Fabio, F., Rijas Llimpe, F.L., Brandes, A.A., Marzola, M., Montesarchio, V., Rea, A., Genua, G., Casaretti, R., Silvestro, L., Montano, M., Sarobba, M.G., Sanna, G., Filippelli, G., Dima, G., Greco, E., Roselli, M., Natale, D., Condemi, G., Fumi, G., Tafuto, S., Masullo, P., Tiberio, G., de Manzoni, G., Fiorentini, G., Mazzanti, R., Carlomagno, C., De Stefano, A., Cartenì, G., and Otero, M.

Published
2014
Full Text
View/download PDF

4. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer

Author

Bajetta, E., Floriani, I., Di Bartolomeo, M., Labianca, R., Falcone, A., Di Costanzo, F., Comella, G., Amadori, D., Pinto, C., Carlomagno, C., Nitti, D., Daniele, B., Mini, E., Poli, D., Santoro, A., Mosconi, S., Casaretti, R., Boni, C., Pinotti, G., Bidoli, P., Landi, L., Rosati, G., Ravaioli, A., Cantore, M., Di Fabio, F., Aitini, E., Marchet, A., Floriani, I., Rulli, E., Cropalato Di Tullio, M., Poli, D., Galli, F., Biagioli, E., De Simone, I., Poli, D., Mangano, S., Tonato, M., Zucca, E., Valsecchi, MG., Floriani, I., Bajetta, E., Di Bartolomeo, M., Labianca, R., Amadori, D., Falcone, A., Di Costanzo, F., Daniele, B., Pinto, C., Comella, G., Nitti, D., Mini, E., De Placido, S., Marchet, A., Bajetta, E., Di Bartolomeo, M., Catena, L., Schiavo, M., Pinotti, G., Proserpio, I., Rosati, G., Bordonaro, R., Cordio, S., Burrafato, G., Bochicchio, A.M., Aieta, M., Fazio, N., Spada, F., Amoroso, V., Marini, G., Soto Parra, H., Novello, G., Massidda, B., Ionta, M.T., Comandè, M., Venezia, R., Bertolini, A., Menatti, E., Zanlorenzi, L., Colombo, A., Iop, A., Bonura, S., Mazza, E., Viganò, M., Ardizzoia, A., DellʼOro, S., Lo Re, G., Santeufemia, D., Buonadonna, A., Luisi, D., Ucci, G., Di Lucca, G., Bonetti, A., Bergamo, F., Alù, M., Vastola, F., Marchetti, P., Corsi, D.C., Massa, E., Di Pinto, G., Duro, M., Oliani, C., Franchini, M., Inzoli, A., Gebbia, N., Repetto, L., Rota, S., Frontini, L., Labianca, R., Mosconi, S., Quadri, A., De Grossi, S., Bidoli, P., Cazzaniga, M.E., Villa, F., Foa, P., Ferrari, D., Aitini, E., Rabbi, C., Barni, S., Petrelli, F., Giordano, M., Luchena, G., Pirovano, M., Nasisi, A., Catalano, V., Giordani, P., Zaniboni, A., Leone, F., Ferrario, S., Beretta, G.D., Menichetti, E.T., Conte, D., Mari, D., Giannicola, R., Pierantoni, C., Luporini, A.G., Ravaioli, A., Tassinari, D., Nicolini, M., Amadori, D., Frassineti, G.L., Turci, D., Zumaglini, F., Tamberi, S., Piancastelli, A., Cruciani, G., Falcone, A., Landi, L., Minuti, G., Cantore, M., Orlandi, M., Mambrini, A., Ciarlo, A., Cavaciocchi, D., Del Monte, F., Ricci, S., Brunetti, M.I., Lencioni, M., Sisani, M., Sozzi, P., Granetto, C., Chiara, S., Galetto, A.S., Ribecco, A.S., DeCensi, A., Ciuffreda, L., Baldini, E.E., Camisa, R., Todeschini, R., Santoro, A., Rimassa, L., Carnaghi, C., Pressiani, T., Boni, C., Rondini, E., Gnoni, R., Di Costanzo, F., Gasperoni, S., Cavanna, L., Palladino, M.A., Mattioli, R., Laici, G., Pucci, F., Alessio, M.D., Bernardini, I., Tomasello, G., Baldino, G., Rossetti, R., Giaquinta, S., Pinto, C., Di Fabio, F., Rijas Llimpe, F.L., Brandes, A.A., Marzola, M., Montesarchio, V., Rea, A., Daniele, B., Genua, G., Casaretti, R., Silvestro, L., Montano, M., Sarobba, M.G., Sanna, G., Filippelli, G., Dima, G., Greco, E., Roselli, M., Natale, D., Condemi, G., Fumi, G., Tafuto, S., Masullo, P., Nitti, D., Marchet, A., Tiberio, G., de Manzoni, G., Fiorentini, G., Mazzanti, R., Carlomagno, C., De Stefano, A., Cartenì, G., and Otero, M.

Published
2014
Full Text
View/download PDF

6. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study

Author

Iacopetta, B., Russo, A., Bazan, V., Dardanoni, G., Gebbia, N., Soussi, T., Kerr, D., Elsaleh, H., Soong, R., Kandioler, D., Janschek, E., Kappel, S., Lung, M., Leung, C.-S.S., Ko, J.M., Yuen, S., Ho, J., Leung, S.Y., Crapez, E., Duffour, J., Ychou, M., Leahy, D.T., O'Donoghue, D.P., Agnese, V., Cascio, S., Di Fede, G., Chieco-Bianchi, L., Bertorelle, R., Belluco, C., Giaretti, W., Castagnola, P., Ricevuto, E., Ficorella, C., Bosari, S., Arizzi, C.D., Miyaki, M., Onda, M., Kampman, E., Diergaarde, B., Royds, J., Lothe, R.A., Diep, C.B., Meling, G.I., Ostrowski, J., Trzeciak, L., Guzińska-Ustymowicz, K., Zalewski, B., Capellá, G.M., Moreno, V., Peinado, M.A., Lönnroth, C., Lundholm, K., Sun, X.F., Jansson, A., Bouzourene, H., Hsieh, L.-L., Tang, R., Smith, D.R., Allen-Mersh, T.G., Khan, Z.A.J., Shorthouse, A.J., Silverman, M.L., Kato, S., and Ishioka, C.

Published
2006
Full Text
View/download PDF

28. Clinical and Experimental Projects on Chemotherapy of Bladder Tumours

Author

Pavone-Macaluso, M., Rausa, L., Gebbia, N., Caramia, G., Rizzo, F.P., Arena, E., Tessitore, V., and Vecchioni, M.

Abstract

Our clinical and experimental experience with chemotherapy of bladder tumours is reviewed. The routes of drug administrations, drug dosages and combinations, are presented. Adjuvant radiotherapy and chemoprophylaxis of certain tumours are discussed.S. Afr. Med. J., 48, 631 (1974)

Published
2017

30. Addition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and Cyclophosphamide

Author

Papaldo, P., Lopez, M., Cortesi, Enrico, Cammilluzzi, E., Antimi, M., Terzoli, E., Lepidini, G., Vici, P., Barone, C., Ferretti, G., Di Cosimo, S., Nistico, C., Carlini, P., Conti, F., Di Lauro, L., Botti, C., Vitucci, C., Fabi, A., Giannarelli, D., Marolla, P., Di Maio, M., Perrone, F., Gallo, C., Iaffaioli, R. V., Manzione, L., Piantedosi, F. V., Cigolari, S., Illiano, A., Barbera, S., Robbiati, S. F., Piazza, E., Ianniello, G. P., Frontini, L., Veltri, E., Castiglione, F., Rosetti, F., De Maio, E., Maione, P., Gridelli, C., Rossi, A., Barletta, E., Barzelloni, M. L., Signoriello, G., Bilancia, D., Dinota, A., Rosati, G., Germano, D., Lamberti, A., Pontillo, V., Brancacio, L., Crispino, C., Esposito, M., Battiloro, C., Tufano, G., Cioffi, A., Guardasole, V., Angelini, V., Guidetti, G., Renda, F., Romano, F., Volpintesta, A., Sannicolo, M., Filipazzi, V., Esani, G., Gambaro, A., Ferrario, S., Tinessa, V., Caprio, M. G., Zonato, S., Cabiddu, M., Raina, A., D'Aprile, M., Pistillucci, G., Porcile, G., Ostellino, O., Vinante, O., Azzarello, G., Gebbia, V., Borsellino, N., Testa, A., Gasparini, G., Morabito, A., Gattuso, D., Romito, S., Carrozza, F., Fava, S., Calcagno, A., Grimi, E., Bertetto, O., Ciuffreda, L., Parello, G., Maiorino, L., Santoro, A., Santoro, M., Failla, G., Aiello, R. A., Bearz, A., Sorio, R., Scalone, S., Clerici, M., Bollina, R., Belloni, P., Sacco, C., Sibau, A., Adamo, V., Altavilla, G., Scimone, A., Spatafora, M., Bellia, V., Hopps, M. R., Monfardini, S., Favaretto, A., Stefani, M., Corradini, G. M., Pavia, G., Scagliotti, G., Novello, S., Selvaggi, G., Tonato, M., Darwish, S., Michetti, G., Belometti, M. O., Labianca, R., Quadri, A., De Marinis, F., Migliorino, M. R., Martelli, O., Colucci, G., Galetta, D., Giotta, F., Isa, L., Candido, P., Rossi, N., Calandriello, A., Ferrau, F., Malaponte, E., Barni, S., Cazzaniga, M., Gebbia, N., Valerio, Mr, Belli, M., Colantuoni, G., Capuano, M. A., Angiolillo, M., Sollitto, F., Ardizzoia, A., Luporini, G., Locatelli, M. C., Pari, F., Aitini, E., Pedicini, T., Febbraro, A., Zollo, C., Di Costanzo, F., Bartolucci, R., Gasperoni, S., Gaion, F., Palazzolo, G., Galligioni, E., Caffo, O., Cortesi, E., D'Auria, G., Curcio, C., Vasta, M., Bumma, C., Celano, A., Bretti, S., Nettis, G., Anselmo, A., Mattioli, R., Aschelter, A., and Foa, P.

Subjects
Adult, Cancer Research, medicine.medical_specialty, Indazoles, Filgrastim, Cyclophosphamide, medicine.medical_treatment, Breast Neoplasms, Gastroenterology, Disease-Free Survival, chemistry.chemical_compound, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Granulocyte Colony-Stimulating Factor, medicine, Humans, Survival rate, Aged, Epirubicin, Chemotherapy, business.industry, Lonidamine, Middle Aged, medicine.disease, Metastatic breast cancer, Recombinant Proteins, Granulocyte colony-stimulating factor, Surgery, Survival Rate, Oncology, chemistry, Female, business, Follow-Up Studies, medicine.drug
Abstract

Purpose: Lonidamine (LND) can enhance the activity of anthracyclines in patients with metastatic breast cancer. A multicenter, prospective, randomized trial was designed to determine whether the association of LND with high-dose epirubicin plus cyclophosphamide (EC) could improve disease-free survival (DFS) in patients with early breast cancer (BC) compared with EC alone. Granulocyte colony-stimulating factor (G-CSF) was added to maintain the EC dose-intensity. Patients and Methods: From October 1991 to April 1994, 506 patients with stage I/II BC were randomly assigned to four groups: (A) epirubicin 120 mg/m2 and cyclophosphamide 600 mg/m2 administered intravenously on day 1 every 21 days for four cycles (124 patients); (B) EC plus LND 450 mg/d administered orally (125 patients); (C) EC plus G-CSF administered subcutaneously (129 patients); (D) EC plus LND plus G-CSF (128 patients). Results: Median follow-up was 55 months. Five-year DFS rate was similar for LND (B+D groups; 69.6%) versus non-LND arms (A+C groups; 70.3%) and G-CSF (C+D groups; 67.2%) versus non–G-CSF arms (A+B groups; 72.9%). Five-year overall survival (OS) was comparable in LND (79.1%) versus non-LND arms (81.3%) and in G-CSF (80.6%) versus non–G-CSF arms (79.6%). DFS and OS distributions in LND and G-CSF arms did not change according to tumor size, node, receptor, and menopausal status. G-CSF dramatically reduced hematologic toxicity without having a significant impact on dose-intensity (98.1% v 95.5% for C+D and A+B groups, respectively). Conclusion: EC is active and well tolerated in patients with early breast cancer. The addition of LND or G-CSF does not improve DFS or OS.

Published
2003

31. La consulenza genetica in oncologia: implicazioni biomolecolari e cliniche

Author

RUSSO, Antonio, RIZZO, Sergio, Calò, V, GRASSI, Nello, PANTUSO, Gianni, FRAZZETTA, Michele, Guarneri, D, LO DICO, Giuseppe, BUSCEMI, Maria, Gebbia, N, BAZAN, Viviana, Russo, A, Rizzo, S, Calò, V, Grassi, N, Pantuso, G, Frazzetta, M, Guarneri, D, Lo Dico, G, Buscemi, M, Gebbia, N, and Bazan, V

Subjects
Ovarian cancer, Genetic testing, genetic couseling, Hereditary breast cancer
Published
2008

32. Design, Synthesis, and Biological Evaluation of Novel Aminobisphosphonates Possessing an in Vivo Antitumor Activity Through a γδ -T Lymphocytes-Mediated Activation Mechanism

Author

Simoni D., Gebbia N., Invidiata F. P., Eleopra M., Marchetti P., Rondanin R., Baruchello R., Provera S., Marchioro C., Tolomeo M., Kwaasi A., Dunford J., Buccheri S., Caccamo N., Dieli F., MARINELLI, LUCIANA, LIMONGELLI, VITTORIO, NOVELLINO, ETTORE, Simoni, D., Gebbia, N., Invidiata, F. P., Eleopra, M., Marchetti, P., Rondanin, R., Baruchello, R., Provera, S., Marchioro, C., Tolomeo, M., Marinelli, Luciana, Limongelli, Vittorio, Novellino, Ettore, Kwaasi, A., Dunford, J., Buccheri, S., Caccamo, N., and Dieli, F.

Published
2008

33. Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases

Author

gaetano leto, Badalamenti, G., Arcara, C., Crescimanno, M., Flandina, C., Tumminello, F. M., Incorvaia, L., Gebbia, N., Fulfaro, F., LETO, G, BADALAMENTI, G, ARCARA, C, CRESCIMANNO, M, FLANDINA, C, TUMMINELLO, FM, INCORVAIA, L, GEBBIA, N, and FULFARO, F

Subjects
Aged, 80 and over, Male, Bone Density Conservation Agents, Diphosphonates, +acid%22">Zoledronic > acid, Imidazoles, Prostatic Neoplasms, Bone Neoplasms, Breast Neoplasms, Middle Aged, Proteinase, Zoledronic Acid, Cathepsin B, +metalloproteinase-9%22">Matrix > metalloproteinase-9, Matrix Metalloproteinase 9, Matrix metalloproteinase-2, Bone metastasi, Bisphosphonates, Bone metastasis, Proteinases, Urokinase-type plasminogen activator, Humans, Matrix Metalloproteinase 2, Bisphosphonate, Female, Aged
Abstract

Background: The effects of the bisphosphonate derivative zoledronic acid (ZA) on the > circulating levels of matrix metalloproteinase-2 (MMP-2), matrix metallo-proteinases-9 > (MMP-9), cathepsin B (Cath B) and urokinase-type plasminogen activator (uPA) in > patients with bone metastasis (BMTS) and the possible correlation with the symptomatic > response induced by this drug in these patients were evaluated. Patients and Methods: > Proteinase levels were determined by enzyme-linked immunosorbent assay (ELISA) in the > plasma of 30 patients with painful bone metastases from breast or prostate cancer > undergoing multiple treatment with ZA (4 mg i.v., every 4 weeks). Healthy subjects > (HS) of both genders (12 female and 30 male) served as the control group. The > symptomatic response to ZA was assessed by the visual analog scale score (VAS). > Results: The median MMP-2 and MMP-9 pretreatment levels were more elevated in BMTS as > compared to HS (p¡Ü0.0001). Conversely, uPA levels were lower in BMTS p=0.0033; no > significant difference was observed for Cath B. ZA administration was associated with > a symptomatic response (VAS score¡Ü4) in 25/30 patients (83.3%) (p phenomenon paralleled a decrease of Cath B and MMP-2 plasma concentrations from > baseline values on week 12 (p=0.05). A similar trend, although not statistically > significant, was also noted for MMP-9 and uPA. However, no direct relationship was > observed between the analgesic effect induced by ZA and changes in the circulating > levels of these enzymes. Conclusion: These data show that ZA administration may > provide relief from bone pain in patients with diffuse skeletal metastases and confirm > a possible implication of cysteine proteinases and matrix metalloproteinases in bone > metastasis formation, but not in the pathogenesis of metastatic bone pain.

Published
2006

34. Ductal lavage: a valid method of risk assessment and of early diagnosis in breast cancer

Author

Calcara, D., Gregorio, V., Corsale, S., Calo, V., Agnese, V., Augello, C., Bruno, L., Gargano, G., Gullo, A., La Paglia, L., Schiro, V., Terrasi, M., Crosta, A., Badalamenti, G., Fricano, S., Napoli, L., Antonio Giordano, Tomasino, Rm, Morello, V., Daniele, E., Chiarini, A., Martorana, A., Gebbia, N., Bazan, V., Russo, A., CALCARA D, GREGORIO V, CORSALE S, CALO V, AGNESE V, AUGELLO C, BRUNO L, GARGANO G, GULLO A, LA PAGLIA L, SCHIRO, TERRASI M, CROSTA A, BADALAMENTI G, FRICANO S, NAPOLI L, GIORDANO A, TOMASINO RM, MORELLO V, DANIELE E, CHIARINI A, MARTORANA A, GEBBIA N, BAZAN V, and RUSSO A

Published
2006

35. Impact on Survival of Timing and Duration of Adjuvant Chemotherapy in Radically Resected Gastric Cancer

Author

Di Bartolomeo, Maria, primary, Pietrantonio, Filippo, additional, Rulli, Eliana, additional, Poli, Davide, additional, Berenato, Rosa, additional, Caporale, Marta, additional, Bajetta, Emilio, additional, Floriani, Irene, additional, Bajetta, E., additional, Di Bartolomeo, M., additional, Catena, L., additional, Schiavo, M., additional, Pinotti, G., additional, Proserpio, I., additional, Rosati, G., additional, Bordonaro, R., additional, Cordio, S., additional, Burrafato, G., additional, Bochicchio, A.M., additional, Aieta, M., additional, Fazio, N., additional, Spada, F., additional, Amoroso, V., additional, Marini, G., additional, Soto Parra, H., additional, Novello, G., additional, Massidda, B., additional, Ionta, M.T., additional, Comandè, M., additional, Venezia, R., additional, Bertolini, A., additional, Menatti, E., additional, Zanlorenzi, L., additional, Colombo, A., additional, Iop, A., additional, Bonura, S., additional, Mazza, E., additional, Viganò, M., additional, Ardizzoia, A., additional, Dell'Oro, S., additional, Lo Re, G., additional, Santeufemia, D., additional, Buonadonna, A., additional, Luisi, D., additional, Ucci, G., additional, Di Lucca, G., additional, Bonetti, A., additional, Bergamo, F., additional, Alù, M., additional, Vastola, F., additional, Marchetti, P., additional, Corsi, D.C., additional, Massa, E., additional, Di Pinto, G., additional, Duro, M., additional, Oliani, C., additional, Franchini, M., additional, Inzoli, A., additional, Gebbia, N., additional, Repetto, L., additional, Rota, S., additional, Frontini, L., additional, Labianca, R., additional, Mosconi, S., additional, Quadri, A., additional, De Grossi, S., additional, Bidoli, P., additional, Cazzaniga, M.E., additional, Villa, F., additional, Foa, P., additional, Ferrari, D., additional, Aitini, E., additional, Rabbi, C., additional, Barni, S., additional, Petrelli, F., additional, Giordano, M., additional, Luchena, G., additional, Pirovano, M., additional, Nasisi, A., additional, Catalano, V., additional, Giordani, P., additional, Zaniboni, A., additional, Leone, F., additional, Ferrario, S., additional, Beretta, G.D., additional, Menichetti, E.T., additional, Conte, D., additional, Mari, D., additional, Giannicola, R., additional, Pierantoni, C., additional, Luporini, A.G., additional, Ragazzini, A., additional, Ravaioli, A., additional, Tassinari, D., additional, Nicolini, M., additional, Amadori, D., additional, Frassineti, G.L., additional, Turci, D., additional, Zumaglini, F., additional, Tamberi, S., additional, Piancastelli, A., additional, Cruciani, G., additional, Bejtja, E., additional, Falcone, A., additional, Landi, L., additional, Minuti, G., additional, Cantore, M., additional, Orlandi, M., additional, Mambrini, A., additional, Ciarlo, A., additional, Cavaciocchi, D., additional, Del Monte, F., additional, Ricci, S., additional, Brunetti, I.M., additional, Lencioni, M., additional, Sisani, M., additional, Sozzi, P., additional, Granetto, C., additional, Chiara, S., additional, Galetto, A.S., additional, Ribecco, A.S., additional, DeCensi, A., additional, Ciuffreda, L., additional, Baldini, E.E., additional, Camisa, R., additional, Todeschini, R., additional, Santoro, A., additional, Rimassa, L., additional, Carnaghi, C., additional, Pressiani, T., additional, Boni, C., additional, Rondini, E., additional, Gnoni, R., additional, Di Costanzo, F., additional, Gasperoni, S., additional, Cavanna, L., additional, Palladino, M.A., additional, Mattioli, R., additional, Laici, G., additional, Pucci, F., additional, Alessio, M.D., additional, Bernardini, I., additional, Tomasello, G., additional, Baldino, G., additional, Rossetti, R., additional, Giaquinta, S., additional, Pinto, C., additional, Di Fabio, F., additional, Rijas Llimpe, F.L., additional, Brandes, A.A., additional, Marzola, M., additional, Rummo Benevento, A.O.G., additional, Competiello, S., additional, Montesarchio, V., additional, Rea, A., additional, Daniele, B., additional, Genua, G., additional, Licenziato, M., additional, Casaretti, R., additional, Silvestro, L., additional, Montano, M., additional, Sarobba, M.G., additional, Sanna, G., additional, Filippelli, G., additional, Dima, G., additional, Greco, E., additional, Roselli, M., additional, Natale, D., additional, Condemi, G., additional, Fumi, G., additional, Tafuto, S., additional, Masullo, P., additional, Nitti, D., additional, Marchet, A., additional, Tiberio, G., additional, de Manzoni, G., additional, Nobili, S., additional, Fiorentini, G., additional, Mazzanti, R., additional, Perrotta, E., additional, Carlomagno, C., additional, De Stefano, A., additional, Cartenì, G., additional, and Otero, M., additional

Published
2016
Full Text
View/download PDF

37. p53 mutations in L3-loop zinc-binding domain, DNA-ploidy, and S phase fraction are independent prognostic indicators in colorectal cancer: A prospective study with a five-year follow-up

Author

Russo, A., Migliavacca, M., Zanna, I., Valerio, M. R., Latteri, M. A., Grassi, N., Pantuso, G., Sergio Salerno, Dardanoni, G., Albanese, I., La Farina, M., Tomasino, R. M., Gebbia, N., Bazan, V., Russo, A, Migliavacca, M, Zanna, I, Valerio, MR, Latteri, MA, Grassi, N, Pantuso, G, Salerno, S, Dardanoni, G, Albanese, I, La Farina, M, Tomasino, RM, Gebbia, N, and Bazan, V

Subjects
Male, Settore MED/06 - Oncologia Medica, protein p53, S Phase, Biomarkers, Tumor, Humans, Prospective Studies, Codon, Aged, Ploidies, Polymorphism, Genetic, DNA, Neoplasm, Exons, DNA, Middle Aged, Genes, p53, Prognosis, Survival Analysis, Protein Structure, Tertiary, Italy, Multivariate Analysis, Mutation, Female, Carrier Proteins, Colorectal Neoplasms, Follow-Up Studies
Abstract

p53 gene alterations are among the most common events observed in colorectal cancer,and are accompanied frequently by DNA aneuploidy and high proliferative activity. The prognostic significance of such mutations remains controversial. We prospectively evaluated the prognostic significance of p53 mutations, DNA-ploidy, and S phase fraction (SPF) in a consecutive series of 160 colorectal cancer patients (median follow-up 71 months). Tumor DNA was screened for p53 mutations by PCR/single-strand conformational polymorphism/sequencing. DNA-ploidy and SPF were assessed by DNA flow cytometry. p53 mutations were detected in 68 of 160 (42.5%) cases. In 56% (38 of 68) of these, p53 mutations were found in conserved areas of the gene and in 44% (30 of 68 cases) outside the conserved regions. Eighteen of the 68 cases (26%) had mutations in the L3 loop, 11 of 68 (16%) in the L1 loop-sheet-alpha helix motif, and 39 of 68 (58%) outside L3 and loop-sheet-alpha helix. Seventy-five percent of the cases (120 of 160) showed DNA aneuploidy, whereas 18% of these (22 of 120) were multiclonal. The major independent predictors for both disease relapse and death were advanced Dukes' stage, p53 mutations affecting L3 loop, DNA-aneuploid tumors, and high SPF (18.5%). Our results show that mutations in L3 functional domain, more than any mutations, are important biological indicators to predict the outcome of patients indicating that these mutations have biological relevance in terms of colorectal cancer disease course.

Published
2002

39. Hereditary common cancers: molecular and clinical genetics

Author

Russo, A., Ines Zanna, Tubiolo, C., Migliavacca, M., Bazan, V., Latteri, M. A., Tomasino, R. M., Gebbia, N., Russo A., Zanna I., Tubiolo C., Migliavacca M., Bazan V., Latteri M.A., Tomasino R.M., and Gebbia N.

Subjects
Male, Models, Genetic, Settore MED/06 - Oncologia Medica, BRCA gene, Risk Assessment, Hereditary cancer, Pedigree, APC gene, Neoplasms, Biomarkers, Tumor, Animals, Humans, Female, Genes, Tumor Suppressor, Genetic Predisposition to Disease, MMR genes
Abstract

This review focuses on the functional role and structural features of the genes involved in common hereditary cancers. Most of these tumors are sporadic and the genetic alterations responsible for their genesis take place over several cell generations; nevertheless, 5 to 10% of the human tumors are hereditary, with a rapid development. Cancer susceptibility genes have been classified as "gatekeepers" (e.g. RB1, ki-ras) and "caretakers" (e.g. hMLH1 and hMSH2, BRCA1). The first step in identifying individuals at high risk of developing a specific inherited form of cancer, and who should therefore undergo genetic tests, is the detailed construction of family history (an accurate cancer family history that includes at least three generation pedigrees, an appropriate cancer risk assessment and an effective genetic counseling). At present, the most useful methods of risk assessment are those performed on the following genes: BRCA1 and BRCA2 especially for hereditary breast and ovarian cancer, hMLH1 and hMSH2 for hereditary non polyposis colorectal cancer, APC for familial adenomatous polyposis, ret for medullary thyroid carcinoma, p53 for the Li-Fraumeni syndrome, p16 for melanoma and RB1 for retinoblastoma. In conclusion, the development of new diagnostic tests will permit a more accurate assessment of risk in individuals who have not so far shown any sign or symptom of the disease.

Published
2001

40. An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

Author

Grünwald, V, Karakiewicz, P, Bavbek, S, Miller, K, Machiels, J, Lee, S, Larkin, J, Bono, P, Rha, S, Castellano, D, Blank, C, Knox, J, Hawkins, R, Anak, O, Rosamilia, M, Booth, J, Pirotta, N, Bodrogi, I, Romedi, M, Ferrandini, S, Rondinon, M, Pittman, K, Goldstein, D, Shapiro, J, Troon, S, Yip, D, Mainwaring, P, Zigeuner, R, Loidl, W, Greil, R, Schmidinger, M, De Grève, J, Rottey, S, Vermorken, J, Gil, T, Gennigens, C, Roumeguere, T, Barrios, C, Mathias, C, Assi, H, Hotte, S, Spadafora, S, Wood, L, Zalewski, P, Mackensie, M, Bjarnason, G, Lalancette, A, Chan, A, Higgins, B, North, S, Soulieres, D, Asselah, J, Sperlich, C, Miller, W, Yadav, S, El Maraghi, R, Godoy, J, Prausová, J, Katolicka, J, Petruzelka, L, Kiss, I, Lapela, M, Bergmann, L, Beck, J, Jäger, E, Kindler, M, Overkamp, F, Wirth, M, Hölzer, W, Gschwend, J, Stenzl, A, Gauler, T, Niederwieser, D, Marschner, N, Lück, A, Tessen, H, Eichelberg, C, Steiner, T, Goebell, P, Kettner, E, Bakhshandeh Bath, A, Wilhelm, M, Schmitz, S, Jacob, A, Bierer, S, Kube, U, Staehler, M, Engel, E, Frambach, M, Schellenberger, U, Albers, P, Simon, J, Gleissler, M, Klotz, T, Repp, R, Kröning, H, Westermann, J, Rebmann, U, Brehmer, B, Niederle, N, Grund, C, Verpoort, K, Fonara, P, Rassweiler, J, Bamias, A, Fountzilas, G, Razis, E, Mouratidou, D, Georgoulias, V, Samantas, E, Mangel, L, Szanto, J, Berger, R, Pe'Er, A, Sella, A, Ben Yosef, R, Nechushtan, H, Crinò, L, Bracarda, S, Ciuffreda, L, Graiff, C, Falcone, A, Roselli, M, Sternberg, C, Santoro, A, Ruggeri, E, Bearz, A, Venturini, M, Aglietta, M, Amadori, D, Di Costanzo, F, Bari, M, Gebbia, N, Conte, P, Bonetti, A, Bordonaro, R, Cascinu, S, Contu, A, Cruciani, G, Gasparro, D, Nardi, M, Lelli, G, Lo Re, G, Boccardo, F, Lorusso, V, Maiello, E, Manente, P, Passalacqua, R, Piantedosi, F, Porta, C, Sacco, C, Tondini, C, De Placido, S, Carteni, G, Dogliotto, L, Rosti, G, Milella, M, Roila, F, Amoroso, D, Farina, G, Al Khatib, H, Kim, T, Ahn, J, Lim, H, Chung, I, Kim, J, Chung, J, Ghosn, M, Shameseddine, A, Lugo, R, Cabrera, P, Osanto, S, Groenewegen, G, van den Eertwegh, F, van Herpen, C, Oosting, S, Soetekouw, P, Lilleby, W, Klepp, O, Guren, T, Alcedo, J, Karlov, P, Nosov, D, Roman, L, Rusakov, I, Bazarbashi, S, Toh, C, Mardiak, J, del Muro Solans, F, Ray, J, Mollins, J, Martinez, I, Gonzalez, B, Santasusana, M, Piqueras, M, Fuentes, J, Larriba, J, Caro, R, Garcia, A, Aparicio, L, Lopez, N, Aragon, V, Morales, C, Figueiras, M, Ibanez, J, Billalabeitia, G, Estrada, E, Arranz, J, Sorrosal, J, Lozano, A, de Villena, M, Espinosa, E, Lopez, R, Perez, J, Laurell, A, Stierner, U, Cwikiel, M, Borner, M, Dietrich, P, Rothermundt, C, Pu, Y, Chang, Y, Ou, Y, Chuang, C, Liao, Y, Srimuninnimit, V, Sriuranpong, V, Buyukberber, S, Yalcin, B, Goker, E, Yalcin, S, Geldart, T, Wagstaff, J, Nicholson, S, Chowdhury, S, Bahl, A, Jones, R, Azzabi, A, Chao, D, Fife, K, Mead, G, Nathan, P, Pandha, H, Hajdenberg, J, Gabrail, N, Nimeh, N, Logan, T, Flaig, T, Schraeder, R, Rini, B, O'Rourke, M, Alemany, C, Kessinger, A, Amin, A, Arriaga, M, Rodriguez, J, Gauler, Thomas (Beitragende*r), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, and Laboratory of Molecular and Medical Oncology

Subjects
Nephrology, Oncology, Male, Cancer Research, mTOR inhibitor, Settore MED/06 - Oncologia Medica, Medizin, Advanced kidney cancer, RAD001, REACT, 0302 clinical medicine, Renal cell carcinoma, Receptors, 80 and over, Treatment Failure, Neoplasm Metastasis, Aged, 80 and over, 0303 health sciences, Vascular Endothelial Growth Factor, Sirolimus, Young Adult, Antineoplastic Agents, Humans, Aged, Immunosuppressive Agents, Protein Kinase Inhibitors, Receptors, Vascular Endothelial Growth Factor, Kidney Neoplasms, Adult, Carcinoma, Renal Cell, Middle Aged, Female, 3. Good health, 030220 oncology & carcinogenesis, Safety, medicine.drug, medicine.medical_specialty, SECOND LINE THERPAY, Second-line therapy, Everolimus, 03 medical and health sciences, Internal medicine, medicine, Adverse effect, 030304 developmental biology, business.industry, Carcinoma, Renal Cell, medicine.disease, Surgery, Clinical trial, Expanded access, business, Kidney cancer
Abstract

BACKGROUND AND OBJECTIVES: The RECORD-1 trial established the clinical benefit of everolimus in patients with metastatic renal cell carcinoma (mRCC) after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy. The REACT (RAD001 Expanded Access Clinical Trial in RCC) study was initiated to address an unmet medical need by providing everolimus prior to commercial availability, and also to further assess the safety and efficacy of everolimus in patients with VEGFr-TKI-refractory mRCC. PATIENTS AND METHODS: REACT (Clinicaltrials.gov: NCT00655252) was a global, open-label, expanded-access programme in patients with mRCC who were intolerant of, or who had progressed on or after stopping treatment with, any available VEGFr-TKI therapy. Patients received everolimus 10mg once daily, with dose and schedule modifications allowed for toxicity. Patients were closely monitored for the development of serious and grades 3/4 adverse events (AEs). Response was assessed by RECIST every 3months for the first year and every 6months thereafter. RESULTS: A total of 1367 patients were enroled. Safety findings and tumour responses were consistent with those observed in RECORD-1, with no new safety issues identified. The most commonly reported serious AEs were dyspnoea (5.0%), pneumonia (4.7%) and anaemia (4.1%), and the most commonly reported grades 3/4 AEs were anaemia (13.4%), fatigue (6.7%) and dyspnoea (6.5%). Best overall response was stable disease in 51.6% and partial response in 1.7% of patients. Median everolimus treatment duration was 14weeks. CONCLUSION: Everolimus is well tolerated in patients with mRCC and demonstrates a favourable risk-benefit ratio.

Published
2012

41. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial

Author

Cognetti, F, Ruggeri, Em, Felici, A, Gallucci, M, Muto, G, Pollera, Cf, Massidda, B, Rubagotti, A, Giannarelli, D, Boccardo, F, Cantiani, R, Adamo, Vincenzo, Aglietta, M, Bertetto, O, Cetto, Gl, Orlandini, P, Ferrazzi, E, Nardi, M, Manzione, L, Porcile, G, Lentini, M, Breda, E, Gamucci, T, Tummarello, D, Dogliotti, L, Tumolo, S, Motta, M, Lo Russo, V, De Grande, G, Sacco, C, Gaion, F, Lavarello, A, Nuzzo, A, Clerico, M, Aragona, C, Gernone, A, Morelli, F, Cupini, Mattioli, R, Marra, A, Antimi, M, Silingardi, V, Labianca, R, Martoni, A, Bortolussi, V, Luoni, M, Rosabian, A, Di Vito, F, Catalano, G, and Gebbia, N.

Subjects
bladder cancer adjuvant chemotherapy phase III trial
Published
2012

42. Observational study to evaluate the pattern of trastuzumab (T) use and survival outcomes in HER2-positive (HER2+) early breast cancer (EBC): Regional Southern Italy experience

Author

Adamo, Vincenzo, Ricciardi, GIUSEPPINA ROSARIA, Adamo, Barbara, Agostara, B., Caruso, M., Gebbia, V., Gebbia, N., Lavenia, G., Banna, G. L., Mafodda, A., Rossello, R., Butera, A., Spada, S., Borsellino, N., Mangiameli, A., Campiglio, M., Tuccari, Giovanni, and on behalf AIOM SIAPEC Sicilian Group

Published
2011

45. Short term intensive preoperative chemotherapy with high doses of epirubicin plus G-CSF rescue for locally advanced Stage III breast carcinoma

Author

GEBBIA, Vittorio, LATTERI, Mario, CIPOLLA, Calogero, Agostara, B, Valenza, R, Comandè, S, Callari, A, Blasi, L, Buccellato, C, Gebbia, N., Gebbia, V, Latteri, MA, Agostara, B, Valenza, R, Comandè, S, Callari, A, Blasi, L, Cipolla, C, Buccellato, C, and Gebbia, N

Subjects
Settore MED/18 - Chirurgia Generale, Settore MED/06 - Oncologia Medica, Breast carcinoma, preoperative chemotherapy, G.CSF
Published
1996

49. Flow cytometric DNA analysis and lysosomal cathepsins B and L in locally advanced laryngeal cancer. Relationship with clinicopathologic parameters and prognostic significance

Author

Russo A., Bazan V., Gebbia N., Pizzolanti G., Tumminello F. M., Dardanoni G., Ingria F., Restivo S., Tomasino R. M., Leto G., Russo A., Bazan V., Gebbia N., Pizzolanti G., Tumminello F.M., Dardanoni G., Ingria F., Restivo S., Tomasino R.M., and Leto G.

Subjects
Adult, Aged, 80 and over, Male, Cathepsin L, DNA, Neoplasm, Middle Aged, Aneuploidy, Flow Cytometry, Prognosis, Cathepsins, Cathepsin B, S Phase, Cysteine Endopeptidases, Endopeptidases, Humans, Female, cathepsin B and L, DNA ploidy, flow cytometry, laryngeal squamous cell carcinoma, S‐phase fraction, Lysosomes, Laryngeal Neoplasms, Aged
Abstract

Background. The traditional factors of locally advanced laryngeal squamous cell carcinoma (LSCC) have limited predictive value for the identification of high risk patients. Therefore, it is extremely important to define prognostic factors that identify the more aggressive types. Reliable and reproducible prognostic indicators are being investigated to help clinicians identify high risk groups and address more rational treatment. Methods. Flow cytometric DNA ploidy and S‐phase fraction (SPF) measurements were performed on frozen tumor tissues from a consecutive series of 71 patients with Stage III and IV LSCC. Lysosomal cathepsin B and L activity levels were determined biochemically in matched paired sets of tumor tissue and normal mucosa samples. Results. By univariate analysis, lymph node positivity, poor histologic differentiation, DNA aneuploidy, high SPF, and high tumor/mucosa ratio of cathepsin B activity were significantly related to risk of relapse, whereas only DNA aneuploidy and high SPF proved to be significantly related to risk of death. Multivariate analysis showed that high histologic grade and high SPF values (>15.1%) were independent prognostic factors related to risk of relapse (relative risk [RR] = 3.54; 95% confidence limits [CL] = 1.05‐12.0; and RR = 4.22; CL = 1.54‐11.6, respectively), whereas only high SPF was related to risk of death (RR = 3.63; CL = 1.17‐11.3). Conclusions. S‐phase fraction is an independent predictor of relapse free and overall survival in patients with locally advanced LSCC. On the basis of these findings, SPF should be used in addition to other established prognostic factors to refine the prognostic assessment of these patients further. More studies are needed for a better evaluation of the prognostic significance of DNA ploidy and that of lysosomal cysteine proteinases in these tumors. Cancer 1995; 76:1757–64. Copyright © 1995 American Cancer Society

Published
1995

50. Stefin A and cathepsin B and L circulating serum levels in patients with malignant or non-malignant liver diseases: A preliminary report

Author

Tumminello, F. M., Pizzolanti, G., Gebbia, N., gaetano leto, Tumminello F.M., Pizzolanti G., Gebbia N., and Leto G.

Subjects
Hepatocellular carcinoma, Cathepsin L, Lysosomal proteinase, Stefin A, Cathepsin B, Liver cirrhosi
Abstract

Experimental and clinical studies have recently shown a significant correlation between increased activity levels of lysosomal proteinases Cathepsin B, L in tumor tissues and malignant progression. On the basis of these findings we have undertaken some preliminary studies to evaluate the clinical impact of these enzymes and their intracellular inhibitor Stefin A in patients with malignant and non malignant liver diseases. The serum levels of Cathepsin B, L and Stefin A resulted significantly increased (mean 7 folds) in patients with liver diseases as compared to healthy subjects . these findings suggest that Cathepsin B, Cathepsin L, and Stefin A serum levels may be potentially useful as prognostic parameters for the clinical and therapeutic management of patients with hepatocellular carcinoma and/or liver cirrhosis

Published
1995

Catalog

Books, media, physical & digital resources
See catalog results